3 years ago

The effects of maraviroc versus efavirenz in combination with zidovudine/lamivudine on the CD4/CD8 ratio in treatment-naïve HIV-infected individuals.

Moreno, Zlotnik, Serrano-Villar, Pérez-Molina, Caruana
A low CD4/CD8 ratio during treated HIV infection reflects heightened immune activation and predicts mortality. The effect of different ART regimens on CD4/CD8 ratio recovery remains unclear. We performed a post hoc analysis of the MERIT study, a randomized, double-blind, trial of maraviroc versus efavirenz, in combination with zidovudine-lamivudine, in treatment-naive HIV-infected individuals. We found higher rates of CD4/CD8 ratio normalization with efavirenz, which was driven by greater CD8+ T-cell decline.

Publisher URL: http://doi.org/10.1128/AAC.01763-17

DOI: 10.1128/AAC.01763-17

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.